Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats

Apoptosis

Volumn 18, Issue 12, 2013, Pages 1481-1491

  Kim, Do Young ^a,b   Chung, Sook In ^a,b   Ro, Simon Weonsang ^a,b   Paik, Yong Han ^c   Lee, Jung Il ^a,b   Jung, Man Kil ^d   Lee, Min Goo ^a   Park, Young Nyun ^a,b   Lee, Kwan Sik ^a,b   Park, Jung Gyu ^e   Park, Hee Dong ^e   Han, Kwang Hyub ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Centre   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Yonsei University   (South Korea)

^e LG Chemical Ltd   (South Korea)

Author keywords

Antioxidant; Caspase inhibitor; Hepatic fibrosis; Rat

Indexed keywords

4 HYDROXYNONENAL; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA SMOOTH MUSCLE ACTIN; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CASPASE 7; CASPASE 9; CASPASE INHIBITOR; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA1; GELATINASE A; INTERLEUKIN 1BETA CONVERTING ENZYME; MALONALDEHYDE; NIVOCASAN; SERUM ALBUMIN; THIOACETAMIDE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPSY; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; LIVER INJURY; MALE; MORPHOMETRICS; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL;

RATTUS;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CASPASE INHIBITORS; CASPASES; COLLAGEN TYPE I; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; HUMANS; LIVER CIRRHOSIS; MALE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84889094639     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0896-5     Document Type: Article

References (35)

1. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134:1655-1669
2. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209-218
3. Ellis RE, Yuan JY, Horvitz HR (1991) Mechanisms and functions of cell death. Annu Rev Cell Biol 7:663-698
4. Reed JC, Tomaselli KJ (2000) Drug discovery opportunities from apoptosis research. Curr Opin Biotechnol 11:586-592
5. Nicholson DW (2000) From bench to clinic with apoptosis-based therapeutic agents. Nature 407:810-816
6. Reed JC (2002) Apoptosis-based therapies. Nat Rev Drug Discov 1:111-121
7. MacBride CB, McPhail LT, Steeves JD (1999) Emerging therapeutic targets in caspase-dependent disease. Emerg Ther Targets 3:391-411
8. Patel T (2000) Apoptosis in hepatic pathophysiology. Clin Liver Dis 4:295-317
9. Thorburn A (2004) Death receptor-induced cell killing. Cell Signal 16:139-144
10. Parola M, Robino G (2001) Oxidative stress-related molecules and liver fibrosis. J Hepatol 35:297-306
11. Koek GH, Liedorp PR, Bast A (2011) The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 412:1297-1305
12. 2 and cyclooxygenase-2. J Bio Chem 275:20136-20145
13. Kim KM, Kim YM, Park M, Park K, Chang HK, Park TK et al (2000) A broad-spectrum caspase inhibitor blocks concanavalin A-induced hepatitis in mice. Clin Immunol 97:221-233
14. Paik YH, Yoon YJ, Lee HC, Jung MK, Kang SH, Chung SI et al (2011) Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats. Exp Mol Med 43:341-349
15. Jung M, Lee HC, Ahn CW, Park W, Choi S, Kim H et al (2002) Effective isolation of magnesium lithospermate B and its inhibition of aldose reductase and fibronectin on mesangial cell line. Chem Pharm Bull 50:1135-1136
16. Malekzadeh R, Mohamadnejad M, Rakhshani N, Nasseri-Moghaddam S, Merat S, Tavangar SM et al (2004) Reversibility of cirrhosis in chronic hepatitis B. Clin Gastroenterol Hepatol 2:344-347
17. Pockros PJ (2009) Antifibrotics for chronic hepatitis C. Clin Liver Dis 13:365-373
18. Liaw YF (2011) Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver Int 31(Suppl 1):117-121
19. Guicciardi ME, Gores GJ (2005) Apoptosis: a mechanism of acute and chronic liver injury. Gut 54:1024-1033
20. Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P et al (2010) Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol 53:542-550
21. Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH et al (2007) Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 46:324-329
22. DeMinicis S, Seki E, Oesterreicher C, Schnable B, Schwabe RF, Brenner DA (2008) Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cell (HSC). Hepatology 48:2016-2026
23. Ratziu V, Sheikh MY, Sanyal AJ, Lim JK, Conjeevaram H, Chalasani N et al (2012) A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 55:419-428
24. Hsu YC, Lin YL, Chiu YT, Shiao MS, Lee CY, Huang YT (2005) Antifibrotic effects of Salvia miltiorrhiza on dimethylnitrosamine-intoxicated rats. J Biomed Sci 12:185-195
25. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ (2002) Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 123:1323-1330
26. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J et al (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9:347-351
27. Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ (2004) The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 308:1191-1196
28. Strobel Swanson L, Korsmeyer S, Cannistra SA (1996) BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 93:14094-14099
29. Masuoka HC, Guicciardi ME, Gores GJ (2009) Caspase inhibitors for the treatment of hepatitis C. Clin Liver Dis 13:467-475
30. Nakamoto Y, Kaneko S, Fan H, Momoi T, Tsutsui H, Nakanishi K et al (2002) Prevention of hepatocellular carcinoma development associated with chronic hepatitis B by anti-fas ligand antibody therapy. J Exp Med 196:1105-1111
31. MacDonald GA, Bridle KR, Ward PJ, Walker NI, Houglum K, George DK et al (2001) Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominantly in acinar zone 3. J Gastroenterol Hepatol 16:599-606
32. Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA et al (2006) Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 43:435-443
33. Jiang JX, Mikami K, Venugopal S, Li Y, Torok NJ (2009) Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. J Hepatol 51:139-148
34. 2 and cyclooxygenase-2. J Biol Chem 275:20136-20145
35. Gu K, Zhao JD, Ren ZG, Ma NY, Lai ST, Wang J et al (2011) A natural process of cirrhosis resolution and deceleration of liver regeneration after thioacetamide withdrawal in a rat model. Mol Biol Rep 38:1687-1696